Mucroporin, the First Cationic Host Defense Peptide from the Venom of Lychas mucronatus

被引:78
作者
Dai, Chao [1 ]
Ma, Yibao [1 ]
Zhao, Zhenhuan [1 ]
Zhao, Ruiming [1 ]
Wang, Qian [1 ]
Wu, Yingliang [1 ]
Cao, Zhijian [1 ]
Li, Wenxin [1 ]
机构
[1] Wuhan Univ, Coll Life Sci, State Key Lab Virol, Wuhan 430072, Hubei, Peoples R China
关键词
D O I
10.1128/AAC.00542-08
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The misuse of antibiotics has led our age to a dangerous edge, as antibiotic-resistant pathogens appear to evolve more quickly than antibiotics are invented. Thus, new agents to treat bacterial infection are badly needed. Cationic host defense peptides are on the first line of a host defense system and are thought to be good candidates for treating bacterial infection. Here, a novel cationic host defense peptide, mucroporin, was cloned and characterized from the venom of Lychas mucronatus. The MIC for Staphylococcus aureus was 25 mu g/ml, including antibiotic-resistant pathogens. Based on the molecular template of mucroporin, mucroporin-M1 was designed by amino acid substitution. The MIC for S. aureus was 5 mu g/ml, including the antibiotic-resistant pathogens methicillin-resistant S. aureus, methicillin-resistant coagulase-negative Staphylococcus, penicillin-resistant S. aureus, and penicillin-resistant S. epidermidis. Moreover, mucroporin-M1 also inhibited gram-negative bacteria. The modes of action of mucroporin and mucroporin-M1 were both rapid killing by disrupting the cell membrane of bacteria, and the number of surviving bacteria was reduced by about 4 to 5 orders of magnitude immediately after peptide delivery. These results showed that mucroporin could be considered a potential anti-infective drug, especially for treating antibiotic-resistant pathogens.
引用
收藏
页码:3967 / 3972
页数:6
相关论文
共 53 条
[1]   Cationic antimicrobial peptides:: update of clinical development [J].
Andrès, E ;
Dimarcq, JL .
JOURNAL OF INTERNAL MEDICINE, 2004, 255 (04) :519-520
[2]   The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus [J].
Appelbaum, PC .
CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 :16-23
[3]   MRSA - the tip of the iceberg [J].
Appelbaum, PC .
CLINICAL MICROBIOLOGY AND INFECTION, 2006, 12 :3-10
[4]   Early vancomycin-resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course [J].
Avery, R ;
Kalaycio, M ;
Pohlman, B ;
Sobecks, R ;
Kuczkowski, E ;
Andresen, S ;
Mossad, S ;
Shamp, J ;
Curtis, J ;
Kosar, J ;
Sands, K ;
Serafin, M ;
Bolwell, B .
BONE MARROW TRANSPLANTATION, 2005, 35 (05) :497-499
[5]  
Bianchi L, 1998, CANCER RES, V58, P815
[6]  
BOMAN HG, 1995, ANNU REV IMMUNOL, V13, P61, DOI 10.1146/annurev.iy.13.040195.000425
[7]   Cationic antimicrobial peptides - Issues for potential clinical use [J].
Bradshaw, JP .
BIODRUGS, 2003, 17 (04) :233-240
[8]   Antimicrobial peptides: Pore formers or metabolic inhibitors in bacteria? [J].
Brogden, KA .
NATURE REVIEWS MICROBIOLOGY, 2005, 3 (03) :238-250
[9]   Antimicrobial peptides in animals and their role in host defences [J].
Brogden, KA ;
Ackermann, M ;
McCray, PB ;
Tack, BF .
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 22 (05) :465-478
[10]   Cationic host defense (antimicrobial) peptides [J].
Brown, KL ;
Hancock, REW .
CURRENT OPINION IN IMMUNOLOGY, 2006, 18 (01) :24-30